Raised IL1β at 0–4 weeks after COVID-19 onset was strongly predictive of persistent PASC at 24 weeks after COVID-19 onset, and warrants further exploration as a possible predictive biomarker for PASC. This evidence concerns the gene IL1B and COVID-19.